This recombinant Mouse Leucine zipper putative tumor suppressor 1 (Lzts1) protein is produced using an E. coli expression system and includes the full mature protein from amino acids 2 to 599. The protein comes tagged with a C-terminal 6xHis, which makes purification and detection more straightforward. It is provided with a purity level exceeding 85%, confirmed by SDS-PAGE analysis, which should give reliable results for research use.
Leucine zipper putative tumor suppressor 1 (Lzts1) appears to be a protein involved in cell cycle regulation and is considered a potential tumor suppressor. It seems to play a crucial role in maintaining genomic stability and has become a subject of interest in cancer research due to its implications in cell proliferation and apoptosis pathways. Understanding what Lzts1 actually does may be essential for gaining insights into tumorigenesis and developing therapeutic strategies.
Potential Applications
Note: The applications listed below are based on what we know about this protein's biological functions, published research, and experience from experts in the field. However, we haven't fully tested all of these applications ourselves yet. We'd recommend running some preliminary tests first to make sure they work for your specific research goals.
Based on the provided information, the recombinant mouse Lzts1 is expressed in E. coli, a prokaryotic system that may not support proper folding of this eukaryotic tumor suppressor protein. Lzts1 contains functional domains, including leucine zipper motifs that require specific folding and potentially post-translational modifications for activity. While the protein is full-length mature (2-599aa) with a C-terminal 6xHis tag and >85% purity, the E. coli expression system lacks eukaryotic chaperones and modification machinery. Since activity is unverified, the protein cannot be assumed to be correctly folded or bioactive without experimental validation.
1. Protein-Protein Interaction Studies Using His-Tag Pull-Down Assays
The C-terminal 6xHis tag enables technical feasibility for pull-down assays, but if Lzts1 is misfolded, the leucine zipper domain may not interact properly with biological partners. Identified interactions could be non-physiological. This application requires prior validation of proper folding and leucine zipper functionality to ensure biologically relevant results.
2. Antibody Development and Validation
This application is appropriate. The recombinant Lzts1 can serve as an effective immunogen for antibody generation. The full-length sequence provides comprehensive epitope coverage, and the His-tag facilitates purification and detection. Even if misfolded, antibodies may recognize linear epitopes useful for detection assays.
3. Biochemical Characterization and Stability Studies
This application is well-suited and should be prioritized. Techniques like circular dichroism spectroscopy and size-exclusion chromatography can directly assess protein folding and oligomerization state. These studies are valuable for characterizing the recombinant Lzts1 protein regardless of bioactivity status.
4. In Vitro Functional Assays for Leucine Zipper Domain Analysis
This application is high-risk without activity verification. If Lzts1 is misfolded, dimerization assays and functional studies will yield misleading results. The leucine zipper domain requires precise conformation for proper function. This application should only be pursued after confirming native folding.
Final Recommendation & Action Plan
Given the uncertainty in folding and bioactivity, recommend first performing biophysical characterization (circular dichroism for secondary structure, analytical ultracentrifugation for oligomeric state) to assess protein folding. Antibody development can proceed immediately, while interaction and functional studies should await folding validation. Always include proper controls and validate key findings with native Lzts1 when possible.
